Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GP2013

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Background Biosimilars are innovative therapeutic drugs which offer a cheaper alternation for biological which used for… Expand
Is this relevant?
2017
2017
BACKGROUND GP2013 is a rituximab biosimilar developed to stringent development guidelines, including non-clinical and preclinical… Expand
Is this relevant?
2017
2017
3075 Background: Development of a biosimilar involves extensive characterization of the originator product and a target-directed… Expand
Is this relevant?
2017
2017
Abstract The introduction of biosimilars can increase the availability of effective and life-saving therapies, while reducing… Expand
Is this relevant?
2017
2017
Objectives The aim of this report is to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence as well as similar… Expand
  • figure 1
  • figure 2
Is this relevant?
2016
2016
Background GP2013 has been developed as a proposed biosimilar to originator rituximab (RTX), by Sandoz, a Novartis Company. The… Expand
Is this relevant?
2014
2014
Abstract Biosimilar development involves a target-directed iterative process to ensure a similar product to the originator. Here… Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BackgroundRegulatory approval for a biosimilar product is provided on the basis of its comparability to an originator product. A… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?